Protein kinase C-θ is required for NK cell activation and in vivo control of tumor progression

Journal of Immunology

Volumn 182, Issue 4, 2009, Pages 1972-1981

  Aguiló, Juan I ^a   Garaude, Johan ^b   Pardo, Julián ^a,c   Villalba, Martín ^b   Anel, Alberto ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b CNRS   (France)

^c Aragón Research and Devlopment Foundation   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE C THETA; HLA ANTIGEN CLASS 1; ISOENZYME; PRKCQ PROTEIN, MOUSE; PROTEIN KINASE C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CELL ACTIVATION; CELL FUNCTION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; IMMUNOSURVEILLANCE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR; TUMOR ESCAPE; TUMOR GROWTH; ANIMAL; CYTOTOXICITY; DISEASE COURSE; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE MUTANT;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; DISEASE PROGRESSION; ENZYME ACTIVATION; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOLOGIC SURVEILLANCE; ISOENZYMES; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; PROTEIN KINASE C; TUMOR ESCAPE;

EID: 61449168882     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0801820     Document Type: Article

References (50)

1. Baier, G., D. Telford, K. M. Giampa, K. M. Coggeshall, G. Baier-Bitterlich, N. Isakov, and A. Altman. 1993. Molecular cloning and characterization of PKCθ, a human novel member of the protein kinase C (PKC) gene family expressed predominantly in hematopoietic cells. J. Biol. Chem. 268: 4997-5004.
2. Isakov, N., and A. Altman. 2002. Protein kinase C θ in T cell activation. Annu. Rev. Immunol. 20: 761-794.
3. Sun, Z., C. W. Arendt, W. Ellmeier, E. M. Schaeffer, M. J. Sunshine, L. Gandhi, J. Annes, D. Petrzilka, A. Kupfer, P. L. Schwartzberg, and D. R. Littman. 2000. PKC-θ is required for TCR-induced NF-κB activation in mature but not in immature T lymphocytes. Nature 404: 402-407.
4. 2+ mobilization and NFAT cell activation in primary mouse T cells. J. Exp. Med. 197: 1525-1535.
5. 2+ signaling by PKCθ in restimulated T cells via a Tec kinase-dependent pathway. Eur. J. Immunol. 34: 2001-2011.
6. Altman, A., and M. Villalba. 2003. Protein kinase C-θ (PKC-θ): it's all about location, location, location. Immunol. Rev. 192: 53-63.
7. Villalba, M., P. Bushway, and A. Altman. 2001. PKCθmediates a selective T cell survival signal via phosphorylation of BAD. J. Immunol. 166: 5955-5963.
8. Bertolotto, C., L. Maulon, N. Filippa, G. Baier, and P. Auberger. 2000. Protein kinase C θ and ε promote T-cell survival by a rsk-dependent phosphorylation and inactivation of BAD. J. Biol. Chem. 275: 37246-37250.
9. + T cells. J. Immunol. 175: 5126-5134.
10. L. J. Immunol. 176: 6709-6716.
11. Aptsiauri, N., A. Cabrera, A. García-Lora, M. A. López-Nevot, F. Ruiz-Cabello, and F. Garrido. 2007. MHC class I antigens and immune surveillance in transformed cells. Int. Rev. Cytol. 256: 139-189.
12. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
13. Dunn, G. P., C. M. Koebel, and R. D. Schreiber. 2006. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6: 836-848.
14. Koebel, C. M., W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig, L. J. Old, M. J. Smyth, and R. D. Schreiber. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450: 903-907.
15. Melief, C. J. M. 2007. Immune pact with the enemy. Nature 450: 803-804.
16. Garaude, J., S. Kaminski, S. Cherni, J. I. Aguiló, C. Jacquet, M. Plays, F. Rodriguez, J. Hernández, R. A. Hipskind, A. Anel, and M. Villalba. 2008. Impaired anti-leukemic immune response in PKCθ-deficient mice. Mol. Immunol. 45: 3463-3469.
17. Ljunggren, H. G., and K. Karre. 1985. Host resistance directed selectively against H-2-deficient lymphoma variants: analysis of the mechanism. J. Exp. Med. 162: 1745-1795.
18. Terme, M., E. Ullrich, N. F. Delahaye, N. Chaput, and L. Zitvogel. 2008. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 9: 486-494.
19. Vivier, E., E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini. 2008. Functions of natural killer cells. Nat. Immunol. 9: 503-510.
20. Pardo, J., S. Balkow, A. Anel, and M. M. Simon. 2002. Granzymes are critically involved in NK-mediated control of RMA-S tumor growth in vivo. Eur. J. Immunol. 32: 2881-2886.
21. Van den Broek, M. F., D. Kägi, R. M. Zinkernagel, and H. Hengartner. 1995. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur. J. Immunol. 25: 3514-3516.
22. Screpanti, V., R. P. A. Wallin, H. G. Ljunggren, and A. Grandien. 2001. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J. Immunol. 167: 2068-2073.
23. Moretta, A., E. Marcenaro, S. Parolini, G. Ferlazzo, and L. Moretta. 2008. NK cells at the interface between innate and adaptive immunity. Cell Death Differ. 15: 226-233.
24. 3 on the activation of natural killer cells: role of protein kinase C and extracellular calcium. Exp. Mol. Pathol. 67: 63-74.
25. Vyas, Y. M., H. Maniar, and B. Dupont. 2002. Differential segregation of the SRC homology 2-containing protein tyrosine phosphatase-1 within the early NK cell immune synapse distinguishes noncytolytic from cytolytic interactions. J. Immunol. 168: 3150-3154.
26. Krzewski, K., X. Chen, J. S. Orange, and J. L. Stromminger. 2006. Formation of a WIP-, WASp-, actin-, and myosin IIA-containing multiprotein complex in activated NK cells and its alteration by KIR inhibitory signaling. J. Cell Biol. 173: 121-132.
27. -/- mice stimulated with interleukin-12 are deficient in production of interferon-γ. J. Leukocyte Biol. 83: 1267-1276.
28. Kärre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678.
29. Kiessling, R., E. Klein, and H. Wigzell. 1975. "Natural" killer cells in the mouse: I. Cytotoxic cells with specificity for Moloney leukemia cells: specificity and distribution according to genotype. Eur. J. Immunol. 5: 112-117.
30. Miltenyi, S., W. Muller, W. Weichel, and A. Radbruch. 1990. High gradient magnetic cell separation with MACS. Cytometry 11: 231-238.
31. Freeley, M., Y. Volkov, D. Kelleher, and A. Long. 2005. Stimulus-induced phosphorylation of PKCθ at the C-terminal hydrophobic-motif in human T lymphocytes. Biochem. Biophys. Res. Commun. 334: 619-630.
32. Smyth, M. J., J. M. Kelly, A. G. Baxter, H. Körner, and J. D. Sedgwick. 1998. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J. Exp. Med. 188: 1611-1619.
33. Smyth, M. J., K. Y. T. Thia, S. E. A. Street, E. Cretney, J. A. Trapani, M. Taniguchi, T. Kawano, S. B. Pelikan, N. Y. Crowe, and D. I. Godfrey. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191: 661-668.
34. Kelly, J. M., P. K. Darcy, J. L. Markby, D. I. Godfrey, K. Takeda, H. Yagita, and M. J. Smyth. 2002. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3: 83-90.
35. Vosshenrich, C. A. J., T. Ranson, S. I. Samson, E. Corcuff, F. Colucci, E. E. Rosmaraki, and J. P. DiSanto. 2005. Roles for common cytokine receptor γ-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J. Immunol. 174: 1213-1221.
36. Glas, R., L. Franksson, C. Une, M. L. Eloranta, C. Ohlen, A. Orn, and K. Kärre. 2000. Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype: an adaptive component of NK cell-mediated responses. J. Exp. Med. 191: 129-138.
37. Pardo, J., M. Buferne, M. J. Martínez-Lorenzo, J. Naval, A. M. Schmitt-Verhulst, C. Boyer, and A. Anel. 2003. Differential implication of PKC isoforms in TCR/CD3-induced Fas ligand expression and in CTL degranulation. Int. Immunol. 15: 1441-1450.
38. Tassi, I., M. Cella, R. Presti, A. Colucci, S. Gilfillan, D. R. Littman, and M. Colonna. 2008. NK cell activating receptors require PKCθ for sustained signaling, transcriptional activation and IFN-γ secretion. Blood 112: 4109-4116.
39. 2+-independent T cell-mediated cytotoxicity. J. Exp. Med. 177: 195-200.
40. Akazawa, T., T. Ebihara, M. Okuno, Y. Okuda, M. Shingai, K. Tsujimura, T. Takahashi, M. Ikawa, M. Okabe, N. Inoue, et al. 2007. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc. Natl. Acad. Sci. USA 104: 252-257.
41. Fehniger, T. A., S. F. Cai, X. Cao, A. J. Bredemeyer, R. M. Presti, A. R. French, and T. J. Ley. 2007. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 26: 798-811.
42. Grybko, M. J., A. T. Pores-Fernando, G. A. Wurth, and A. Zweifach. 2007. Protein kinase C activity is required for cytotoxic T cell lytic granule exocytosis, but the θ isoform does not play a preferential role. J. Leukocyte Biol. 81: 509 -519.
43. Puente, L. G., J. S. He, and H. L. Ostergaard. 2006. A novel PKC regulates ERK activation and degranulation of cytotoxic T lymphocytes: plasticity in PKC regulation of ERK. Eur. J. Immunol. 36: 1009-1018.
44. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413: 732-738.
45. Djeu, J. Y., J. A. Heinbaugh, H. T. Holden, and R. B. Herberman. 1979. Role of macrophages in the augmentation of mouse NK cell activity by poly(I:C) and interferon. J. Immunol. 122: 182-188.
46. Cooper, M. A., T. A. Fehniger, J. B. VanDeusen, R. E. Waite, Y. Liu, H. L. Aguila, and M. A. Caligiuri. 2002. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100: 3633-3638.
47. Basak, G. W., L. Zapala, P. J. Wysocki, A. Mackiewicz, M. Jakobisiak, and W. Lasek. 2008. Interleukin 15 augments antitumor activity of cytokine genemodified melanoma cell vaccines in a murine model. Oncol. Rep. 19: 1173-1179.
48. Cerwenka, A., and L. L. Lanier. 2001. Natural killer cells, viruses and cancer. Nat. Rev. Immunol. 1: 41-49.
49. Gilfillan, S., E. L. Ho, M. Cella, W. M. Yokoyama, and M. Colonna. 2002. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat. Immunol. 3: 1150-1155.
50. Cerwenka, A., J. L. Baron, and L. L. Lanier. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98: 11521-11526.